ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1119

Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis

Kailey Singh1, Harrison Zucker1, Alice Kwon2, Audrey Liu3, Josephine Rini1, Elena Katzap4, Sonali Narain5 and Galina Marder6, 1Northwell Health at Northshore/Long Island Jewish, Manhasset, 2Northwell Health at Northshore/Long Island Jewish, Bayside, NY, 3Loma Linda University, Loma Linda, CA, 4Northwell Health, Great NY, NY, 5Northwell Health, Great Neck, NY, 6Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY

Meeting: ACR Convergence 2024

Keywords: Cardiovascular, Cohort Study, TNF-blocking Antibody

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Management of cardiac sarcoidosis remains controversial. Our study aimed to describe our experience using tumor necrosis factor-α-inhibitors (aTNF) in cardiac sarcoidosis treatment.

Methods: This is a retrospective analysis of patients with cardiac sarcoidosis from Northwell Health Rheumatology. Demographics, clinical characteristics, positron emission tomography (PET) and ejection fraction (EF) from either PET or echocardiogram (ECHO) were collected. Patients were grouped as non aTNF, early aTNF start (<2 years of diagnosis), and late aTNF start (>2 years after diagnosis). Two patients, one early aTNF and one late aTNF, had a pre-aTNF EF, but no EF available post aTNF use. They were reassigned to non aTNF group for paired EF analysis, but for baseline and survival analysis, they remained in the original groups. Composite severity PET score (utilizing perfusion, FDG uptake, number of cardiac segments and right ventricular (RV) involvement) was calculated (0-3 – mild; 3-7 – moderate; 5-11- severe). Change in PET severity score or > 10% absolute EF from baseline defined improved, worsened or stable response. Annualized EF change was computed. Descriptive statistics, the Kruskal Wallis, Fisher’s exact, and ANOVA Friedman tests were used to compare groups for continuous and categorical variables.

Results: The demographic and clinical characteristics of 29 patients with cardiac sarcoidosis are shown in Table 1. Paired EF analysis was performed on 24 patients with >2 follow-up EF including 2 reassigned to non aTNF group. In paired PET analysis, 17 patients with >2 PET scans were included. Survival was similar for all groups, 80% (8/10) in non-aTNF, 86% (6/7) in late aTNF and 92% (11/12) in early aTNF. In the non aTNF group, 4 patients received a cardiac transplant. Most patients with RV involvement were in the early aTNF group (7/12; 58%), vs the non aTNF (1/10; 10%) and late aTNF (2/7; 29%) (p = 0.06) Table 1. There was no difference between groups in baseline EF (p = 0.9) and PET score (p = 0.07) (Fig 2). Annualized EF improvement in early aTNF was significantly higher compared to late aTNF group (p = 0.02) and non aTNF group (p = 0.008) with no difference between the non aTNF and late aTNF groups (p = 0.9) Figure 1a. Although the time for follow-up varied among patients, 1/10 (10%) early aTNF patients had >10% EF decline compared to 6/9 (67%) non aTNF and 2/5 (40%) late aTNF patients but the time of follow-up varied between patients. Improvement in PET score was seen in 5/9 (56%) early aTNF, 3/5 (60%) late aTNF and 1/3 (33%) in non aTNF group Figure 2 c,d. At baseline, 8/12 (67%) early aTNF patients were on 7mg (SD7.17) daily prednisone dose, 4/7 (57%) late TNF patients were on 19mg (SD 22.68), and 7/10 (70%) non aTNF were on 25mg (SD 21.21). Over time 20% (2/10) of non aTNF were at a higher dose than baseline compared to 10% (1/10) of the early aTNF and 16% (1/6) of late aTNF groups.

Conclusion: In this cohort, early aTNF use was associated with improvement in yearly EF change compared to none or late users, suggesting prescribing aTNF early may be associated with EF protection. Slightly higher proportions of non and late aTNF remained on steroids compared to early aTNF. Further research on use and timing of aTNF in cardiac sarcoidosis is warranted.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: K. Singh: None; H. Zucker: None; A. Kwon: None; A. Liu: None; J. Rini: None; E. Katzap: None; S. Narain: None; G. Marder: None.

To cite this abstract in AMA style:

Singh K, Zucker H, Kwon A, Liu A, Rini J, Katzap E, Narain S, Marder G. Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/treatment-outcomes-of-tnf-%ce%b1-inhibitors-in-cardiac-sarcoidosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/treatment-outcomes-of-tnf-%ce%b1-inhibitors-in-cardiac-sarcoidosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology